My research focuses on the use of advanced MRI techniques, combined with other cutting edge imaging and non-imaging biomarkers, to detect, characterise and track early neurodegeneration in Alzheimer’s disease, across both familial and sporadic forms of the disease. I have a particular interest in developing sensitive, quantitative imaging biomarkers of cortical microstructure, and improving our understanding of the association between molecular pathology and downstream early neuronal loss. I am currently the PI of a study using ultra-high field 7T MRI in familial Alzheimer’s disease mutation carriers. I have also previously published studies in multiple other methodological modalities, including blood and CSF based biomarkers, PET, and novel measures of early cognitive decline, with the ultimate aim of understanding how best to combine and utilise such markers to optimise clinical trials design.